Merck & Co.
AWARDS
NEWS
As a monotherapy, Keytruda showed non-inferiority to standard of care but missed the mark as a combination treatment.
Renal cell carcinoma is also called renal cell cancer or renal cell adenocarcinoma. Approximately 90% of all kidney cancers are renal cell carcinomas.
Possibly in response to a trend for Medicare-for-All initiatives, healthcare stocks plunged this week. This largely affected companies like UnitedHealth, which fell 3.2%, Anthem, dropping by 6.8%, and Cigna Corp., sliding 5.1%.
An analysis of efficacy outcomes by causative pathogens showed that clinical and microbiologic response rates for Zerbaxa were comparable to meropenem for Gram-negative respiratory tract pathogens.
There’s little doubt that Merck’s checkpoint inhibitor Keytruda (pembrolizumab) is about as close to a miracle drug as we get.
The study, which uses data gathered from Great Places to Work, points to the company’s openness from its leadership and the treatment of its employees as the primary reason it took the top spot.
JOBS
IN THE PRESS